Compare Kokoh Exa Nusantara Tbk (KOCI) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kokoh Exa Nusantara Tbk vs Organon Pharma Indonesia Tbk. — how do they compare? Kokoh Exa Nusantara Tbk trades at Rp134 (market cap 576.31B, 60.42M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Kokoh Exa Nusantara Tbk is far larger — about 5.5× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| KOCI | SCPI | |
|---|---|---|
Market Cap | 576.31B | 104.4B |
Volume | 60.42M | — |
Lot | 604.22K | — |
Turnover | 7.95B | — |
Average Price | 131.63 | — |
Value | 7.95B | — |
Indicative Equilibrium Price | 134 | — |
Indicative Equilibrium Volume | 5.59K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kokoh Exa Nusantara Tbk
PT Kokoh Exa Nusantara Tbk (the Entity) was established based on Notarial Deed No. 173, dated July 31, 2019 of Dwi Rossulliati, S.H., notary in Mojokerto Regency. The Entity started its commercial operations in 2020. PT Exa Nusa Persada is its ultimate parent entity.
Read more on KOCI →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
